Biography

Ms. Finger has been a director of the Company since September 2023 and is a member of the Company’s Governance and Nominations Committee and Compensation Committee. Ms. Finger has over 30 years of biotech and pharmaceutical leadership experience building and optimizing brands and portfolios in the areas of Gene Medicine, Cell Therapy, Oncology, Neurology, Virology, and Metabolics. She has commercialized products in the US, EU, Asia, and globally. Ms. Finger has served as Chief Operating Officer of Vicero Inc. since September 2023, where she leads business operations, including strategic and financial planning, company build and business development. Ms. Finger previously was Chief Commercial Officer at bluebird bio, Inc. (“bluebird”)  (now known as Genetix Biotherapeutics Inc.) from August 2015 to January 2021, where she built the commercial business enterprise in both Europe and the US, and prepared bluebird’s first gene and cell therapy products for market. Prior to bluebird, from May 1993 until May 2014, Ms. Finger was at Bristol-Myers Squibb Company (“BMS”) in roles with increasing responsibility, leading franchises in Virology, Neurology, and Hematology/Oncology. In these roles she led portfolio planning, product development and franchise strategy, and global commercialization. Ms. Finger also served as Managing Director of BMS Australia/NZ and has managed country, regional, and global P&Ls. Ms. Finger serves as an independent director for KeifeRx LLC and previously served as an independent director for VBL Therapeutics (Nasdaq: VBLT) from July 2021 to August 2022 and for Decibel Therapeutics (Nasdaq: DBTX) from December 2021 until its acquisition in September 2023. As a director of Decibel Therapeutics, Ms. Finger served as Chair of the Nominating and Corporate Governance Committee and a member of the Audit Committee. She has been Chair of the Alliance for Regenerative Medicine Gene Therapy Section and served on the Board of the Alliance for Regenerative Medicine Foundation. Ms. Finger also served as a member of the board for The Medicines Australia Industry Association and Member of the Pharmaceutical Strategic Working Group for the Australia Senator for Industry and Innovation. Ms. Finger has a B.A. from St. Lawrence University and an M.B.A. from Duke University Fuqua School of Business. Ms. Finger was chosen to serve on the Board due to her extensive experience as an executive in the biotech and pharmaceutical industry.